| Download ( PDF | 1MB) |
Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA
Blesch, A., Bosserhoff, Anja-Katrin, Apfel, R., Behl, C., Hessdoerfer, B., Schmitt, A., Jachimczak, P., Lottspeich, F., Buettner, R. und Bogdahn, Ulrich (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Research 54 (21), S. 5695-5701.Veröffentlichungsdatum dieses Volltextes: 07 Jun 2011 06:22
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.20993
Zusammenfassung
Growth and progression of malignant melanoma cells is influenced by a complex network of growth-stimulating and -inhibiting factors produced by both the tumor cells and the local environment. Here we report the purification and molecular cloning of a novel growth regulating protein, designated melanoma inhibitory activity (MIA) and provide a preliminary functional characterization. MIA is ...
Growth and progression of malignant melanoma cells is influenced by a complex network of growth-stimulating and -inhibiting factors produced by both the tumor cells and the local environment. Here we report the purification and molecular cloning of a novel growth regulating protein, designated melanoma inhibitory activity (MIA) and provide a preliminary functional characterization. MIA is translated as a 131-amino acid precursor and processed into a mature 107-amino acid protein after cleavage of a putative secretion signal. A murine complementary DNA was isolated that encoded a MIA-protein with 88% amino acid identity. MIA is secreted into the culture supernatant by several malignant melanoma cell lines as an M(r) 11,000 autocrine growth factor and acts as a potent tumor cell growth inhibitor for malignant melanoma cells and some other neuroectodermal tumors, including gliomas. MIA has no homology to any other known protein and, therefore, represents a novel type of growth-regulatory factor. Furthermore, we describe a molecular approach to express functionally active MIA in Escherichia coli, which might be attractive as a future antitumor therapeutical substance.
Alternative Links zum Volltext
Beteiligte Einrichtungen
Details
| Dokumentenart | Artikel | ||||||||||||||||||||||||
| Titel eines Journals oder einer Zeitschrift | Cancer Research | ||||||||||||||||||||||||
| Verlag: | American Association for Cancer Research | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Band: | 54 | ||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 21 | ||||||||||||||||||||||||
| Seitenbereich: | S. 5695-5701 | ||||||||||||||||||||||||
| Datum | 1994 | ||||||||||||||||||||||||
| Institutionen | Medizin > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) | ||||||||||||||||||||||||
| Identifikationsnummer |
| ||||||||||||||||||||||||
| Klassifikation |
| ||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||||||||||||||||||||
| Status | Veröffentlicht | ||||||||||||||||||||||||
| Begutachtet | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||
| An der Universität Regensburg entstanden | Unbekannt / Keine Angabe | ||||||||||||||||||||||||
| URN der UB Regensburg | urn:nbn:de:bvb:355-epub-209932 | ||||||||||||||||||||||||
| Dokumenten-ID | 20993 |
Downloadstatistik
Downloadstatistik